ArticleCancer management and research2026
Neuroimmunological Mechanisms of Xiao-Yao-San Against Chronic Stress-Induced Colorectal Cancer: A Bioinformatics and Single-Cell Sequencing Study.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to integrate bioinformatics, network pharmacology, and single-cell sequencing to explore the potential neuro-immune mechanisms by which the traditional Chinese medicine formula Xiao-Yao-San (XYS) ameliorates chronic stress-induced colorectal cancer (CRC) progression. Methods: Transcriptomic and survival data of CRC patients were obtained from public databases (TCGA, GEO). Combined with literature review, 130 neurotransmitter-related receptor genes (NRGs) were screened, and their expression and prognostic value in CRC were analyzed. Based on 51 XYS components previously identified by UHPLC/Q-TOF-MS, network pharmacology was employed to predict their potential targets (1,228 in total). These targets were intersected with differentially expressed NRGs. Molecular docking was further performed to evaluate the binding affinity between XYS components and receptors. A mouse model of chronic unpredictable mild stress (CUMS) combined with orthotopic CRC transplantation was established. Neurotransmitter levels were measured by mass spectrometry, and 10x Genomics single-cell transcriptomic sequencing was applied to analyze changes in the tumor immune microenvironment. Results: Bioinformatics analysis revealed that 100 NRGs were significantly dysregulated in CRC tissues. After intersecting with XYS targets, 14 potential NRGs were identified, among which seven (ADRA2C, DRD1, GABRA2, HTR1B, HTR1D, HTR2A, HTR2B) showed significant correlation with patient prognosis. Molecular docking demonstrated favorable binding activity between XYS components (such as 8-Debenzoylpaeoniflorin and Sucrose) and the hub NRGs. In vivo experiments confirmed that XYS reversed CUMS-induced abnormalities in tumor and plasma levels of norepinephrine, dopamine, and serotonin. Single-cell sequencing further indicated that XYS reduced the CUMS-induced increase in myeloid-derived suppressor cell (MDSC) proportion and modulated the expression of key NRGs, including HTR2A in macrophages and HTR1B in T cells. KEGG enrichment analysis suggested that neuroactive ligand-receptor interaction and immune-related pathways were significantly regulated upon XYS intervention. Conclusion: XYS modulates neurotransmitter homeostasis and the tumor immune microenvironment in CRC under chronic stress through a multi-component and multi-target manner, which is closely associated with the regulation of key NRGs such as HTR1B and DRD1. This study provides neuro-immunological evidence for the clinical application of XYS in CRC patients with emotional disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.